Related Experiment Video

Updated: Jan 25, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma

Faiz Anwer1, Kevin Mathew Gee2, Ahmad Iftikhar3

  • 1Taussig Cancer Center, Department of Hematology, Medical Oncology, Cleveland Clinic, Cleveland, OH.

Clinical Lymphoma, Myeloma & Leukemia
|May 1, 2019
PubMed

Insights

Understanding genetic mutations and signaling pathways in multiple myeloma (MM) can guide targeted therapies. Identifying these molecular drivers is key to developing personalized treatments and overcoming drug resistance in MM patients.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Multiple myeloma (MM) is a complex hematologic malignancy characterized by genetic heterogeneity.
  • Aberrant signaling pathways and specific mutations drive MM progression and treatment resistance.

Purpose of the Study:

  • To identify key mutations and aberrant signaling pathways in multiple myeloma.
  • To explore their potential as targets for personalized and effective MM therapies.

Main Methods:

  • Review of current literature on genetic alterations and signaling pathways in MM.
  • Analysis of targeted therapies based on identified molecular drivers.

Main Results:

  • Key pathways implicated include RAS, BCL-2, JAK2, NF-κB, PI3K/mTOR, and MYC.
  • Specific mutations (e.g., RAS, BRAF) and translocations (e.g., t(11:14), t(4;14)) are linked to pathway activation.
  • Targeted agents like vemurafenib, cobimetinib, venetoclax, ruxolitinib, bortezomib, and BEZ235 show potential.
  • Histone deacetylase inhibitors, FGFR3 inhibitors (AZD4547), and BET protein antagonists are also relevant.

Conclusions:

  • Understanding MM's genetic complexity and signaling pathways is crucial for precision medicine.
  • Targeting specific molecular alterations offers a promising strategy for improving MM treatment outcomes and overcoming resistance.
Keywords:
Intracellular pathwayMMMutationsPrecision medicineTargeted therapy

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.7K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.3K
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
6.5K
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
9.9K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.9K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
14.4K